Zevra Therapeutics, Inc. SEC filings ZVRA
Zevra Therapeutics, Inc. has 870 filings in SEC EDGAR's recent list, going back to May 6, 2008. Its latest annual report, Form 10-K, was filed on Mar 9, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 3, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 3, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEF 14A | Proxy statement | Apr 20, 2026 | Jun 4, 2026 |
| PRE 14A | Preliminary proxy statement | Apr 6, 2026 | Apr 6, 2026 |
| DEFA14A | Additional proxy material | May 21, 2025 | — |
| DEFA14A | Additional proxy material | May 8, 2025 | — |
| DEFA14A | Additional proxy material | Apr 21, 2025 | — |
| DEFA14A | Additional proxy material | Apr 21, 2025 | — |
| DEFA14A | Additional proxy material | Apr 7, 2025 | — |
| DEFA14A | Additional proxy material | Mar 31, 2025 | — |
| DEFA14A | Additional proxy material | Mar 31, 2025 | — |
| DEFA14A | Additional proxy material | Apr 29, 2024 | — |
| DEFA14A | Additional proxy material | Apr 3, 2024 | — |
| DEF 14A | Proxy statement | Apr 3, 2024 | May 13, 2024 |
| DEFA14A | Additional proxy material | Aug 31, 2023 | — |
| DEFA14A | Additional proxy material | Apr 17, 2023 | — |
| DEFA14A | Additional proxy material | Apr 5, 2023 | — |
| DEFA14A | Additional proxy material | Apr 3, 2023 | — |
| DEFA14A | Additional proxy material | Mar 30, 2023 | — |
| DEFA14A | Additional proxy material | Mar 29, 2023 | — |
| DEFA14A | Additional proxy material | Mar 29, 2023 | — |
| DEFA14A | Additional proxy material | Mar 29, 2023 | — |
| DEFA14A | Additional proxy material | Mar 17, 2023 | — |
| DEFA14A | Additional proxy material | Mar 16, 2023 | — |
| DEFA14A | Additional proxy material | Mar 15, 2023 | — |
| DEFA14A | Additional proxy material | Mar 7, 2023 | — |
| DEFA14A | Additional proxy material | Feb 27, 2023 | — |
| DEFA14A | Additional proxy material | Jun 17, 2022 | — |
| DEFA14A | Additional proxy material | May 12, 2022 | — |
| DEF 14A | Proxy statement | May 12, 2022 | Jun 28, 2022 |
| DEFA14A | Additional proxy material | Apr 30, 2021 | — |
| DEF 14A | Proxy statement | Apr 30, 2021 | Jun 17, 2021 |
| DEFA14A | Additional proxy material | Nov 23, 2020 | — |
| DEFA14A | Additional proxy material | Oct 29, 2020 | — |
| DEFA14A | Additional proxy material | Oct 26, 2020 | — |
| DEF 14A | Proxy statement | Oct 8, 2020 | Oct 27, 2020 |
| DEFA14A | Additional proxy material | Sep 25, 2020 | — |
| PRE 14A | Preliminary proxy statement | Sep 25, 2020 | Sep 25, 2020 |
| DEFA14A | Additional proxy material | May 8, 2020 | — |
| DEF 14A | Proxy statement | May 8, 2020 | Jun 19, 2020 |
| DEFA14A | Additional proxy material | Mar 15, 2019 | — |
| DEF 14A | Proxy statement | Mar 15, 2019 | Apr 24, 2019 |
| DEFA14A | Additional proxy material | Apr 12, 2018 | — |
| DEF 14A | Proxy statement | Apr 12, 2018 | May 22, 2018 |
| DEFA14A | Additional proxy material | Apr 12, 2017 | — |
| DEF 14A | Proxy statement | Apr 12, 2017 | May 23, 2017 |
| DEFA14A | Additional proxy material | Apr 14, 2016 | — |
| DEF 14A | Proxy statement | Apr 14, 2016 | May 24, 2016 |
Showing 46 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ZVRA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1434647
- Former names
- KEMPHARM, INC (until Feb 24, 2023); KEMPHARM INC (until Jun 30, 2011)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.